Skip to content

D&A at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$123.2M-2.9%
Dianthus Therapeutics logo
Dianthus TherapeuticsDNTH
$32K+18.5%
Omeros logo
OmerosOMER
$239K-17.3%
Vor Biopharma logo
Vor BiopharmaVOR
$28K-96.6%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
$79K+3.9%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
$151K-64.6%

Other financials

Income statement

See full
Operating income-$46.1M+19.8%
Net income-$44.1M+18.8%
EPS (diluted)-$0.23+37.8%

Balance sheet

See full
Cash & equivalents$175.2M+80.4%
Total debt$25.4M-10.2%
Total equity$204.5M-16.1%
Total assets$262.9M-13.2%

Cash flow

See full
Operating cash flow-$46.8M+6.5%
CapEx--100%
Free cash flow-$46.8M+6.6%

Valuation

See full
Market cap$868.37M+233%
Enterprise value$718.59M+274%

Returns & leverage

See full
Return on equity-87.6%+42.3pp
Debt / equity0.1×0.0×
Current ratio6.4×-1.6×

Where this comes from

Reported directly by Annexon in its filing.

Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.

The official record: Annexon’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Annexon's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Annexon's D&A?
Annexon (ANNX) reported D&A of $539K in Q1 2026.
How has Annexon's D&A changed year-over-year?
Annexon's D&A increased by 0.4% year-over-year, from $537K to $539K.
What is the long-term trend for Annexon's D&A?
Over 4 years (2021 to 2025), Annexon's D&A has grown at a 0.3% compound annual growth rate (CAGR), from $2.14M to $2.17M.
What does D&A mean?
Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.